Suppr超能文献

蓝藻和微藻聚合物:抗病毒活性与应用

Cyanobacterial and microalgae polymers: antiviral activity and applications.

作者信息

da Silva Mariana Barbalho Farias, Teixeira Cláudia Maria Luz Lapa

机构信息

Laboratório de Genética Microbiana, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

Laboratório de Biotecnologia de Microalgas, Divisão de Energia,Instituto Nacional de Tecnologia, Rio de Janeiro, RJ, Brazil.

出版信息

Braz J Microbiol. 2024 Dec;55(4):3287-3301. doi: 10.1007/s42770-024-01452-5. Epub 2024 Jul 15.

Abstract

At the end of 2019, the world witnessed the beginning of the COVID-19 pandemic. As an aggressive viral infection, the entire world remained attentive to new discoveries about the SARS-CoV-2 virus and its effects in the human body. The search for new antivirals capable of preventing and/or controlling the infection became one of the main goals of research during this time. New biocompounds from marine sources, especially microalgae and cyanobacteria, with pharmacological benefits, such as anticoagulant, anti-inflammatory and antiviral attracted particular interest. Polysaccharides (PS) and extracellular polymeric substances (EPS), especially those containing sulfated groups in their structure, have potential antiviral activity against several types of viruses including HIV-1, herpes simplex virus type 1, and SARS-CoV-2. We review the main characteristics of PS and EPS with antiviral activity, the mechanisms of action, and the different extraction methodologies from microalgae and cyanobacteria biomass.

摘要

2019年末,全世界见证了新冠疫情的开端。作为一种极具侵袭性的病毒感染,全球都在密切关注关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒及其对人体影响的新发现。在此期间,寻找能够预防和/或控制感染的新型抗病毒药物成为研究的主要目标之一。来自海洋资源的新型生物化合物,特别是微藻和蓝细菌,因其具有抗凝血、抗炎和抗病毒等药理益处而备受关注。多糖(PS)和细胞外聚合物(EPS),尤其是那些结构中含有硫酸化基团的,对包括HIV-1、单纯疱疹病毒1型和SARS-CoV-2在内的多种病毒具有潜在的抗病毒活性。我们综述了具有抗病毒活性的PS和EPS的主要特性、作用机制以及从微藻和蓝细菌生物质中提取的不同方法。

相似文献

1
Cyanobacterial and microalgae polymers: antiviral activity and applications.蓝藻和微藻聚合物:抗病毒活性与应用
Braz J Microbiol. 2024 Dec;55(4):3287-3301. doi: 10.1007/s42770-024-01452-5. Epub 2024 Jul 15.
4
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
5
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
8
Janus kinase inhibitors for the treatment of COVID-19.Janus 激酶抑制剂治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD015209. doi: 10.1002/14651858.CD015209.

本文引用的文献

2
Hydroxychloroquine (HCQ) Treatment for Hospitalized Patients with COVID- 19.羟氯喹(HCQ)治疗 COVID-19 住院患者。
Infect Disord Drug Targets. 2022;22(6):e030322201650. doi: 10.2174/1871526522666220303121209.
7
Remdesivir for the treatment of COVID-19.瑞德西韦用于治疗新型冠状病毒肺炎。
Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验